Since 2009 he is an adjunct professor of medicine at the Univ. of Bonn where he worked in Hematology and Oncology from 1989 to 2006 with a research focus on hematological malignancies (esp. acute leukemias, multiple myeloma) and infections in neutropenic patients.
He coordinated the clinical study group “Refractory Multiple Myeloma” and served as Vicechair and Chair (2002-2006) of the Section Antifungal Therapy of the Paul-Ehrlich-Society for Chemotherapy as well as Editor for the Cochrane Hematological Malignancies Group (2003-2006). He coordinated or co-authored medical practice guidelines for several scientific societies including the Germany Society of Hematology and Oncology and the British Society of Hematology.
Before establishing an independent consultancy in March 2018 with a focus on drug development, medical communication and leadership development for medical and scientific talents in the pharmaceutical industry he worked from 2006-2018 as Medical Director Germany, Vice President Medical Affairs and Head of Global Clinical Research and Development Hematology-Oncology (2016-2018; Summit, NJ, USA). His activities included the development of risk management plans for thalidomide and lenalidomide as well as clinical development and regulatory submissions for drugs like lenalidomide (in several indications), azacitidine, enasidenib and luspatercept.
These experiences have facilitated understanding and engagement in the drug development process from different perspectives and have contributed to the current research interest around drug development in the interface between industry, healthcare structures and society with the relevant scientific, economic and people-oriented aspects.
Contact Prof Axel Glasmacher